Kirkbride Center Claimed

About Kirkbride Center

Our medically monitored detoxification program gently weans individuals off of substances which cause withdrawal symptoms, minimizing discomfort and risk of complications with proper medication and supervision. Individuals in our detoxification program have access too much of the same resources and programming offered to our rehab clients and often choose to step down into our onsite residential rehabilitation program. Currently, our detoxification program consists of 20 beds, though we were recently granted a license from the state to expand to 21 beds should there be a demand from the community.
Our residential rehabilitation program of 242 beds includes many different options for treatment modality in both short term and long term levels of care. Services include detoxification, drug free residential rehabilitation, dual-diagnosis disorders, ongoing medication-assisted treatment and pharmacologic blockade.
Kirkbride has distinguished itself as a leader in treating opiate addiction, providing a full range of pharmacotherapies as clinically appropriate for each individual. We offer methadone maintenance, buprenorphrine (Suboxone) and naltrexone (Vivitrol) oral and extended release. These agents are available for both detoxification and maintenance to help mitigate withdrawal symptoms. . As the first inpatient program in the greater Philadelphia area to be licensed by the state to initiate Suboxone maintenance, we have been very careful in creating our program and only partner with established outpatient programs for continuation of Suboxone maintenance. We currently have agreements for Suboxone referrals from programs in Philadelphia, Delaware, and Bucks counties. We also partner with the Treatment Research Center at the University of Pennsylvania, creating opportunities for clients to take advantage of new medications such as injectable naltrexone (Vivitrol).